Jacqueline Nicholas, MD
Neurology · Columbus, OHNPI 1740457886
Payments from drug & device makers
Across 745 payments — averaging $5753.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$2.3M
- Genentech, Inc.$628K
- Biogen$591K
- EMD Serono, Inc.$223K
- Adamas Pharmaceuticals, Inc.$101K
- TG Therapeutics, Inc.$90K
- plus $331K from 15 others
Across 33 payments — averaging $1933.65 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$34K
- Novartis$23K
- Sanofi$3K
- Novartis Pharma AG$3K
- Biogen$781
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 75 | $2,322,366 |
| Genentech, Inc. | 73 | $628,169 |
| Biogen | 64 | $590,991 |
| EMD Serono, Inc. | 170 | $222,719 |
| Adamas Pharmaceuticals, Inc. | 44 | $100,555 |
| TG Therapeutics, Inc. | 75 | $90,148 |
| Sanofi | 56 | $66,983 |
| AstraZeneca | 44 | $54,252 |
| Bristol Myers Squibb | 34 | $48,448 |
| Amgen(2 entities) | 28 | $34,370 |
| Genentech USA, Inc. | 36 | $31,778 |
| E.r. Squibb & Sons, L.L.C. | 12 | $25,149 |
| Merck Healthcare Kgaa | 6 | $21,295 |
| Merck Kgaa | 7 | $19,385 |
| Ares Trading SA | 8 | $18,258 |
| Greenwich Biosciences, Inc. | 1 | $3,834 |
| Roche Products Limited | 4 | $3,144 |
| Novartis Pharma AG | 2 | $2,925 |
| Johnson & Johnson | 1 | $1,350 |
| AbbVie(2 entities) | 4 | $72 |
| Saol Therapeutics Inc. | 1 | $57 |
How this compares
$4,286,248 in reported general payments places this provider in the 95th percentile of 702 neurology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neurology in Columbus
- Jerry MendellColumbus$11.5M
- Douglas ScharreColumbus$6.8M
- Aaron BosterColumbus$6.3M
- Miriam FreimerColumbus$2.5M
- Pierre GiglioColumbus$2M
- Kenneth MankowskiColumbus$1.6M
- Tirisham GyangColumbus$1.5M
- Geoffrey EubankColumbus$1.4M
- Bakri ElsheikhColumbus$918K
- Brendan KelleyColumbus$880K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.